Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers

Pediatr Blood Cancer. 2016 Aug;63(8):1461-4. doi: 10.1002/pbc.26018. Epub 2016 May 2.

Abstract

Programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) pathway blockade has become a promising therapeutic target in adult cancers. We evaluated PD-L1 expression and tumor-infiltrating CD8(+) T cells in formalin-fixed, paraffin-embedded tumor specimens from 53 untreated pediatric patients with eight cancer types: neuroblastoma, extracranial malignant germ cell tumor, hepatoblastoma, germinoma, medulloblastoma, renal tumor, rhabdomyosarcoma, and atypical teratoid/rhabdoid tumor. One rhabdomyosarcoma with the shortest survival exhibited membranous PD-L1 expression and germinoma contained abundant tumor-infiltrating CD8(+) T cells and PD-L1-positive macrophages. The PD-1/PD-L1 pathway tended to be inactive in pediatric cancers.

Keywords: PD-1/PD-L1 blockade; pediatric cancer; tumor-infiltrating lymphocyte.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • B7-H1 Antigen / metabolism*
  • CD8-Positive T-Lymphocytes / immunology*
  • Child
  • Child, Preschool
  • Humans
  • Infant
  • Infant, Newborn
  • Lymphocytes, Tumor-Infiltrating / immunology
  • Macrophages / immunology*
  • Neoplasms / pathology*
  • Programmed Cell Death 1 Receptor / metabolism*
  • Retrospective Studies
  • Tumor Microenvironment / immunology

Substances

  • B7-H1 Antigen
  • CD274 protein, human
  • PDCD1 protein, human
  • Programmed Cell Death 1 Receptor